Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire August 29, 2022

Kymera Announces $150 Million Private Placement Equity Financing

GlobeNewswire August 19, 2022

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

GlobeNewswire August 11, 2022

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire August 9, 2022

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

GlobeNewswire July 27, 2022

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

GlobeNewswire July 8, 2022

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

PR Newswire June 15, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

GlobeNewswire June 1, 2022

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

GlobeNewswire June 1, 2022

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

GlobeNewswire May 20, 2022

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

GlobeNewswire May 5, 2022

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire May 3, 2022

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

GlobeNewswire April 19, 2022

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

GlobeNewswire April 8, 2022

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire March 2, 2022

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

GlobeNewswire February 24, 2022

Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences

GlobeNewswire January 25, 2022

Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors

GlobeNewswire January 18, 2022

Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company

GlobeNewswire January 10, 2022

Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

GlobeNewswire January 4, 2022